Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCLNASDAQ:GMTXNASDAQ:HRMYNASDAQ:MRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$3.61-3.5%$2.55$1.89▼$4.09$1.08B0.363.34 million shs6.19 million shsGMTXGemini Therapeutics$54.50+0.7%$48.22$1.16▼$14.10$2.36B-0.12189,291 shs1.06 million shsHRMYHarmony Biosciences$31.98+0.4%$32.92$26.47▼$41.61$1.84B0.87628,906 shs1.45 million shsMRTXMirati Therapeutics$58.70$58.82$27.30▼$64.41$4.12B0.772.76 million shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics-3.48%+5.87%+76.96%+56.28%+29.39%GMTXGemini Therapeutics+0.40%+8.07%+17.98%+3.38%+24.69%HRMYHarmony Biosciences+0.38%+0.28%-5.16%-3.65%+2.90%MRTXMirati Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCLAbCellera Biologics2.3483 of 5 stars3.41.00.00.03.13.30.0GMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AHRMYHarmony Biosciences4.773 of 5 stars4.61.00.00.02.93.34.4MRTXMirati Therapeutics0.471 of 5 stars0.00.00.04.70.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 2.75Moderate Buy$8.33130.84% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/AHRMYHarmony Biosciences 3.13Buy$53.6367.68% UpsideMRTXMirati Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HRMY, ABCL, GMTX, and MRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025HRMYHarmony BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$61.005/16/2025ABCLAbCellera BiologicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $10.005/15/2025HRMYHarmony BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$44.00 ➝ $48.005/13/2025HRMYHarmony BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/6/2025HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$49.00 ➝ $49.004/28/2025HRMYHarmony BiosciencesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $48.004/16/2025ABCLAbCellera BiologicsKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$4.00 ➝ $5.004/8/2025HRMYHarmony BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.004/8/2025HRMYHarmony BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$28.83M37.37N/AN/A$3.58 per share1.01GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AHRMYHarmony Biosciences$714.73M2.57$2.95 per share10.85$11.56 per share2.77MRTXMirati Therapeutics$12.44M331.01N/AN/A$17.31 per share3.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$162.86M-$0.56N/AN/AN/A-737.56%-15.98%-12.38%8/5/2025 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AHRMYHarmony Biosciences$145.49M$2.6212.2110.280.4720.53%24.32%15.92%8/5/2025 (Estimated)MRTXMirati Therapeutics-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/ALatest HRMY, ABCL, GMTX, and MRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ABCLAbCellera Biologics-$0.17-$0.15+$0.02-$0.15$7.12 million$4.24 million5/6/2025Q1 2025HRMYHarmony Biosciences$0.59$0.78+$0.19$0.78$184.26 million$184.73 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/AMRTXMirati TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A10.1510.15GMTXGemini TherapeuticsN/A71.4971.49HRMYHarmony Biosciences0.223.673.63MRTXMirati TherapeuticsN/A7.547.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%GMTXGemini Therapeutics75.42%HRMYHarmony Biosciences86.23%MRTXMirati TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.90%GMTXGemini Therapeutics12.90%HRMYHarmony Biosciences23.60%MRTXMirati Therapeutics3.26%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500298.42 million212.18 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableHRMYHarmony Biosciences20057.42 million43.87 millionOptionableMRTXMirati Therapeutics58770.15 million67.86 millionOptionableHRMY, ABCL, GMTX, and MRTX HeadlinesRecent News About These CompaniesMirati Therapeutics Stock Price HistoryMay 26, 2025 | investing.comNew GTPase KRAS mutant inhibitors disclosed in Mirati patentDecember 12, 2024 | bioworld.comBMirati Therapeutics Receives Untitled Letter from OPDP for Overstating Cancer Drug EfficacyOctober 15, 2024 | policymed.comPPharma M&A rumour mill grinds out Mirati's name againAugust 16, 2024 | pharmaphorum.comPMirati's Charles Baum takes the helm at Terremoto BiosciencesJuly 25, 2024 | fiercebiotech.comFMirati Therapeutics gets grant for combination therapy for treating kras G12C cancersApril 17, 2024 | pharmaceutical-technology.comPMirati Therapeutics gets grant for combination therapy for treating kras G12C cancersApril 17, 2024 | pharmaceutical-technology.comPHow this insider trader nailed every single stock tradeApril 5, 2024 | finbold.comFThe workforce reduction at Mirati Therapeutics will take place over the next year and impacts more than 400 employees.April 3, 2024 | sandiegouniontribune.comSMirati Therapeutics files patent for inhibitors of KRAS g12dMarch 26, 2024 | pharmaceutical-technology.comPBristol Myers Squibb cuts hundreds of Mirati staffers months after closing $5.8B buyoutMarch 26, 2024 | fiercepharma.comFBristol Myers Squibb concludes acquisition of Mirati TherapeuticsJanuary 26, 2024 | medicaldialogues.inMBristol Myers Squibb completes acquisition of Mirati TherapeuticsJanuary 25, 2024 | pharmabiz.comPMirati Therapeutics Receives Marketing Authorization For KRAZATI From European CommissionJanuary 10, 2024 | markets.businessinsider.comEuropean Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationJanuary 10, 2024 | finance.yahoo.comMirati Therapeutics Inc [MRTX] Stock sold by Insider Christensen Jamie for $0.14 millionJanuary 2, 2024 | knoxdaily.comKEvaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers AcquisitionDecember 25, 2023 | seekingalpha.comBristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 blnDecember 22, 2023 | reuters.comKaruna Therapeutics soars after $14 billion takeover by Bristol MyersDecember 22, 2023 | msn.comCitigroup Downgrades Mirati Therapeutics (MRTX)December 20, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHRMY, ABCL, GMTX, and MRTX Company DescriptionsAbCellera Biologics NASDAQ:ABCL$3.61 -0.13 (-3.48%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$3.60 -0.01 (-0.42%) As of 06/27/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Gemini Therapeutics NASDAQ:GMTX$54.50 +0.37 (+0.68%) As of 06/27/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Harmony Biosciences NASDAQ:HRMY$31.98 +0.12 (+0.38%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$31.98 0.00 (0.00%) As of 06/27/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Mirati Therapeutics NASDAQ:MRTXMirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
